Medical specialists from Qatar tagged as investigators in clinical trials studying Primary Myelofibrosis

Total 11 results

Ahmad Al Sabbagh
Seen in:
- Doha, National Center for Cancer Care & Research (NCCCR)
Trials:
- NCT03116542 (Sub-Investigator)
Conditions:
Dina S Soliman
Seen in:
- Doha, National Center for Cancer Care & Research (NCCCR)
Trials:
- NCT03116542 (Sub-Investigator)
Conditions:
Firyal Ibrahim
Seen in:
- Doha, National Center for Cancer Care & Research (NCCCR)
Trials:
- NCT03116542 (Sub-Investigator)
Conditions:
HALIMA EL OMRI
Seen in:
- Doha, National Center for Cancer Care & Research (NCCCR)
Trials:
- NCT03116542 (Sub-Investigator)
Conditions:
Lajos Szabados
Seen in:
- Doha, National Center for Cancer Care & Research (NCCCR)
Trials:
- NCT03116542 (Sub-Investigator)
Conditions:
Mohamed A Yassin
Seen in:
- Doha, National Center for Cancer Care & Research (NCCCR)
Trials:
- NCT03116542 (Principal Investigator)
Conditions:
Omar M Ismail
Seen in:
- Doha, National Center for Cancer Care & Research (NCCCR)
Trials:
- NCT03116542 (Sub-Investigator)
Conditions:
Sadek A Nehmeh
Seen in:
- Doha, National Center for Cancer Care & Research (NCCCR)
Trials:
- NCT03116542 (Sub-Investigator)
Conditions:
Samah A Kohla
Seen in:
- Doha, National Center for Cancer Care & Research (NCCCR)
Trials:
- NCT03116542 (Sub-Investigator)
Conditions:
Shehab F Mohamed
Seen in:
- Doha, National Center for Cancer Care & Research (NCCCR)
Trials:
- NCT03116542 (Sub-Investigator)
Conditions:
Stefan Guhlke
Seen in:
- Doha, National Center for Cancer Care & Research (NCCCR)
Trials:
- NCT03116542 (Sub-Investigator)
Conditions:

Clinical Trials on Primary Myelofibrosis

The University of Hong Kong

Recruiting

Ropeginterferon Alfa 2b for Early Myelofibrosis

Myelofibrosis | Primary Myelofibrosis, Prefibrotic Stage

Hong Kong
Assaf-Harofeh Medical Center

Unknown

Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis (MRMF01)

Myelofibrosis, Primary | Myelofibrosis, Post PV | Myelofibrosis, Post ET

Israel
Centre Hospitalier Annecy Genevois

Completed

Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis (Ruxo-EPO)

Myelofibrosis; Anemia
University of Kansas Medical Center

Not yet recruiting

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Myelofibrosis，MF
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Puerto Rico, Russian Federation, Serbia, South... and more
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
AbbVie

Active, not recruiting

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Sweden, Turkey
AbbVie

Terminated

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Korea, Republic of, South Africa
National Taiwan University Hospital

Recruiting

Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis

Pre-fibrotic Myelofibrosis

Taiwan
Telios Pharma, Inc.

Recruiting

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Primary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET Myelofibrosis

Spain, United States, France, Poland, Italy, Germany

Medical specialists from Qatar tagged as investigators in clinical trials studying Primary Myelofibrosis

Clinical Trials on Primary Myelofibrosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations